Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report

Jaclyn J. Renfrow, Alisha DeTroye, Michael Chan, Stephen Tatter, Thomas Ellis, Kevin McMullen, Annette Johnson, Ryan Mott, Glenn J. Lesser

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.

Original languageEnglish (US)
Pages (from-to)659-663
Number of pages5
JournalJournal of Neuro-Oncology
Volume107
Issue number3
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Lymphoma
Central Nervous System
Alkylating Agents
B-Cell Lymphoma
Blood-Brain Barrier
Non-Hodgkin's Lymphoma
Bendamustine Hydrochloride
Therapeutics
Recurrence
Brain
Population

Keywords

  • Bendamustine
  • Chemotherapy
  • Recurrent primary CNS lymphoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Renfrow, J. J., DeTroye, A., Chan, M., Tatter, S., Ellis, T., McMullen, K., ... Lesser, G. J. (2012). Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report. Journal of Neuro-Oncology, 107(3), 659-663. https://doi.org/10.1007/s11060-011-0788-x

Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma : A case report. / Renfrow, Jaclyn J.; DeTroye, Alisha; Chan, Michael; Tatter, Stephen; Ellis, Thomas; McMullen, Kevin; Johnson, Annette; Mott, Ryan; Lesser, Glenn J.

In: Journal of Neuro-Oncology, Vol. 107, No. 3, 05.2012, p. 659-663.

Research output: Contribution to journalArticle

Renfrow, JJ, DeTroye, A, Chan, M, Tatter, S, Ellis, T, McMullen, K, Johnson, A, Mott, R & Lesser, GJ 2012, 'Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report', Journal of Neuro-Oncology, vol. 107, no. 3, pp. 659-663. https://doi.org/10.1007/s11060-011-0788-x
Renfrow, Jaclyn J. ; DeTroye, Alisha ; Chan, Michael ; Tatter, Stephen ; Ellis, Thomas ; McMullen, Kevin ; Johnson, Annette ; Mott, Ryan ; Lesser, Glenn J. / Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma : A case report. In: Journal of Neuro-Oncology. 2012 ; Vol. 107, No. 3. pp. 659-663.
@article{fbaa64b7ae3a47538a7cb7e70f70f26a,
title = "Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report",
abstract = "Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.",
keywords = "Bendamustine, Chemotherapy, Recurrent primary CNS lymphoma",
author = "Renfrow, {Jaclyn J.} and Alisha DeTroye and Michael Chan and Stephen Tatter and Thomas Ellis and Kevin McMullen and Annette Johnson and Ryan Mott and Lesser, {Glenn J.}",
year = "2012",
month = "5",
doi = "10.1007/s11060-011-0788-x",
language = "English (US)",
volume = "107",
pages = "659--663",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma

T2 - A case report

AU - Renfrow, Jaclyn J.

AU - DeTroye, Alisha

AU - Chan, Michael

AU - Tatter, Stephen

AU - Ellis, Thomas

AU - McMullen, Kevin

AU - Johnson, Annette

AU - Mott, Ryan

AU - Lesser, Glenn J.

PY - 2012/5

Y1 - 2012/5

N2 - Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.

AB - Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.

KW - Bendamustine

KW - Chemotherapy

KW - Recurrent primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84863961203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863961203&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0788-x

DO - 10.1007/s11060-011-0788-x

M3 - Article

C2 - 22249693

AN - SCOPUS:84863961203

VL - 107

SP - 659

EP - 663

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -